| 词条 | Receptor activated solely by a synthetic ligand |
| 释义 |
A receptor activated solely by a synthetic ligand (RASSL) or designer receptor exclusively activated by designer drugs (DREADD), is a class of chemogenetically-engineered proteins that permit spatial and temporal control of G protein signaling in vivo.[1] Originally differentiated by the approach used to engineer them, RASSLs and DREADDs are often used interchangeably now to represent an engineered G-protein receptor-ligand system.[2] These systems utilize G protein-coupled receptors (GPCR) engineered to respond exclusively to synthetic ligands, like clozapine N-oxide (CNO),[3] and not to their natural ligand(s). Types of RASSLs / DREADDsOne of the first DREADDs was based on the human M3 muscarinic receptor (hM3).[4] Only two point mutations of hM3 were required to achieve a mutant receptor with nanomolar potency for CNO, insensitivity to acetylcholine (ACh) and low constitutive activity and this DREADD receptor was named hM3Dq. M1 and M5 muscarinic receptors have been mutated to create DREADDs hM1Dq and hM5Dq respectively.[4] The most commonly used inhibitory DREADD is hM4Di, derived from the M4 muscarinic receptor that couples with the Gi protein.[4] Another Gi coupled human muscarinic receptor, M2, was also mutated to obtain the DREADD receptor hM2D.[4] Another inhibitory Gi-DREADD is the kappa-opioid-receptor (KOR) DREADD (KORD) which is selectively activated by salvinorin B (SALB).[5] Gs-coupled DREADDs have also been developed. These receptors are also known as GsD and are chimeric receptors containing intracellular regions of the turkey erythrocyte β-adrenergic receptor substituted into the rat M3 DREADD.[6] RASSL / DREADD ligandsA growing number of ligands that can be used to activate RASSLs / DREADDs are commercially available.[7][8] Clozapine N-oxide (CNO) is the prototypical DREADD activator. CNO activates the excitatory Gq- coupled DREADDs: hM3Dq, hM1Dq and hM5Dq and also the inhibitory hM4Di and hM2Di Gi-coupled DREADDs. CNO also activates the Gs-coupled DREADD (GsD) and the β-arrestin preferring DREADD: rM3Darr (Rq(R165L).[9] Recent findings suggest that systemically administered CNO does not readily cross the blood-brain-barrier in vivo and converts to clozapine which itself activates DREADDs. Clozapine is an atypical antipsychotic which has been indicated to show high DREADD affinity and potency. Subthreshold injections of clozapine itself can be utilised to induce preferential DREADD-mediated behaviors. Therefore when using CNO, care must be taken in experimental design and proper controls should be incorporated.[10] DREADD agonist 21 (AKA Compound 21) represents an alternative agonist for muscarinic-based DREADDs and an alternative to CNO. It has been reported that DREADD agonist 21 (Compound 21) has excellent bioavailability, pharmacokinetic properties and brain penetrability and does not undergo back metabolism to clozapine.[11] Perlapine, a drug already approved for treating insomnia in Japan is an activator of Gq-, Gi-, and Gs DREADDs that has structural similarity to CNO.[12]Salvinorin B is a brain penetrant, potent and selective activator of κ-opioid DREADD (KORD).[13] JHU37160 and JHU37152 have been marketed commercially as novel DREADD ligands, active in vivo, with high potency and affinity for hM3Dq and hM4Di DREADDs. Diihydrochloride salts of DREADDs ligands that are water-soluble (but with differing stabilities in solution) have also been commercially developed (see [14][15] for aqueous stability). MechanismRASSLs and DREADDs are families of designer G-protein-coupled receptors (GPCRs) built specifically to allow for precise spatiotemporal control of GPCR signaling in vivo. These engineered GPCRs, called RASSLs (receptors activated solely by synthetic ligands), are unresponsive to endogenous ligands but can be activated by nanomolar concentrations of pharmacologically inert, drug-like small molecules. Currently, RASSLs exist for the interrogation of several GPCR signaling pathways, including those activated by Gs, Gi, Gq, Golf and β-arrestin.[16] A major cause for success of RASSL resources has been open exchange of DNA constructs, and RASSL related resources. The hM4Di-DREADD's inhibitory effects are a result of the CNO's stimulation and resulting activation of the G-protein inwardly rectifying potassium (GIRK) channels. This causes hyperpolarization of the targeted neuronal cell and thus attenuates subsequent activity.[17] UsesGPCRs are the target for some of the most widely used pharmaceuticals to treat diseases that involve virtually all{{vague|reason= syntax is amdbiguous: do these diseases collectively involve nearly all tissues, with each disease involving relatively few tissues, or does each disease involve nearly all, but leave alone a few GPCR-oblivious tissue? Readers deserve a syntax that rules out one of the two cases|date= July 2017}} tissues of the body. Viral expression of DREADD proteins, both in-vivo enhancers and inhibitors of neuronal function, have been used to bidirectionally control behaviors in mice (e.g odor discrimination).[18] Due to their ability to modulate neuronal activity, DREADDs are used as a tool to evaluate both the neuronal pathways and behaviors associated with drug-cues and drug addiction.[19] HistoryStrader and colleagues designed the first GPCR which could be activated only by a synthetic compound[20] and has gradually been gaining momentum. The first international RASSL meeting was scheduled for April 6, 2006. A simple example of the use of a RASSL system in behavioral genetics was illustrated by Mueller et al. (2005) where they showed that expressing a RASSL receptor in sweet taste cells of the mouse tongue led to a strong preference for oral consumption of the synthetic ligand, whereas expressing the RASSL in bitter taste cells caused dramatic taste aversion for the same compound.[21] The attenuating effects of the hM4Di-DREADD were originally explored in 2007, before being confirmed in 2014.[17] References1. ^{{cite journal | vauthors = Roth BL | title = DREADDs for Neuroscientists | journal = Neuron | volume = 89 | issue = 4 | pages = 683–94 | date = February 2016 | pmid = 26889809 | pmc = 4759656 | doi = 10.1016/j.neuron.2016.01.040 }} 2. ^{{cite journal | vauthors = Conklin BR, Hsiao EC, Claeysen S, Dumuis A, Srinivasan S, Forsayeth JR, Guettier JM, Chang WC, Pei Y, McCarthy KD, Nissenson RA, Wess J, Bockaert J, Roth BL | title = Engineering GPCR signaling pathways with RASSLs | journal = Nature Methods | volume = 5 | issue = 8 | pages = 673–8 | date = August 2008 | pmid = 18668035 | pmc = 2703467 | doi = 10.1038/nmeth.1232 }} 3. ^{{cite journal | vauthors = Armbruster BN, Li X, Pausch MH, Herlitze S, Roth BL | title = Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 104 | issue = 12 | pages = 5163–8 | date = March 2007 | pmid = 17360345 | pmc = 1829280 | doi = 10.1073/pnas.0700293104 | bibcode = 2007PNAS..104.5163A }} 4. ^1 2 3 {{Cite journal|last=Armbruster|first=Blaine N.|last2=Li|first2=Xiang|last3=Pausch|first3=Mark H.|last4=Herlitze|first4=Stefan|last5=Roth|first5=Bryan L.|date=2007-03-20|title=Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand|journal=Proceedings of the National Academy of Sciences of the United States of America|volume=104|issue=12|pages=5163–5168|doi=10.1073/pnas.0700293104|issn=0027-8424|pmc=1829280|pmid=17360345|bibcode=2007PNAS..104.5163A}} 5. ^{{Cite journal|last=Vardy|first=Eyal|last2=Robinson|first2=J. Elliott|last3=Li|first3=Chia|last4=Olsen|first4=Reid H. J.|last5=DiBerto|first5=Jeffrey F.|last6=Giguere|first6=Patrick M.|last7=Sassano|first7=Flori M.|last8=Huang|first8=Xi-Ping|last9=Zhu|first9=Hu|date=2015-05-20|title=A New DREADD Facilitates the Multiplexed Chemogenetic Interrogation of Behavior|journal=Neuron|volume=86|issue=4|pages=936–946|doi=10.1016/j.neuron.2015.03.065|issn=1097-4199|pmc=4441592|pmid=25937170}} 6. ^{{Cite journal|last=Conklin|first=Bruce R.|last2=Hsiao|first2=Edward C.|last3=Claeysen|first3=Sylvie|last4=Dumuis|first4=Aline|last5=Srinivasan|first5=Supriya|last6=Forsayeth|first6=John R.|last7=Guettier|first7=Jean-Marc|last8=Chang|first8=W. C.|last9=Pei|first9=Ying|date=August 2008|title=Engineering GPCR signaling pathways with RASSLs|journal=Nature Methods|volume=5|issue=8|pages=673–678|doi=10.1038/nmeth.1232|issn=1548-7105|pmc=2703467|pmid=18668035}} 7. ^{{Cite web|url=https://www.hellobio.com/dreadds/|title=DREADD ligands (CNO / SalB) for neuroscience research|last=|first=|date=|website=HelloBio.com|language=en|archive-url=|archive-date=|dead-url=|access-date=2018-12-05}} 8. ^{{Cite web|url=https://www.tocris.com/product-type/dreadd-ligands|title=DREADD Ligands|website=Tocris Bioscience|language=en-us|access-date=2018-12-05}} 9. ^{{Cite journal|last=Wess|first=Jürgen|last2=Nakajima|first2=Kenichiro|last3=Jain|first3=Shalini|date=July 2013|title=Novel designer receptors to probe GPCR signaling and physiology|journal=Trends in Pharmacological Sciences|volume=34|issue=7|pages=385–392|doi=10.1016/j.tips.2013.04.006|issn=1873-3735|pmc=3758874|pmid=23769625}} 10. ^{{Cite journal|last=Gomez|first=Juan L.|last2=Bonaventura|first2=Jordi|last3=Lesniak|first3=Wojciech|last4=Mathews|first4=William B.|last5=Sysa-Shah|first5=Polina|last6=Rodriguez|first6=Lionel A.|last7=Ellis|first7=Randall J.|last8=Richie|first8=Christopher T.|last9=Harvey|first9=Brandon K.|date=August 4, 2017|title=Chemogenetics revealed: DREADD occupancy and activation via converted clozapine|journal=Science|volume=357|issue=6350|pages=503–507|doi=10.1126/science.aan2475|issn=1095-9203|pmid=28774929|bibcode=2017Sci...357..503G}} 11. ^{{Cite journal|last=Thompson|first=Karen J.|last2=Khajehali|first2=Elham|last3=Bradley|first3=Sophie J.|last4=Navarrete|first4=Jovana S.|last5=Huang|first5=Xi Ping|last6=Slocum|first6=Samuel|last7=Jin|first7=Jian|last8=Liu|first8=Jing|last9=Xiong|first9=Yan|date=2018-09-14|title=DREADD Agonist 21 Is an Effective Agonist for Muscarinic-Based DREADDs in Vitro and in Vivo|journal=ACS Pharmacology & Translational Science|volume=1|issue=1|pages=61–72|doi=10.1021/acsptsci.8b00012}} 12. ^{{Cite journal|last=Chen|first=Xin|last2=Choo|first2=Hyunah|last3=Huang|first3=Xi-Ping|last4=Yang|first4=Xiaobao|last5=Stone|first5=Orrin|last6=Roth|first6=Bryan L.|last7=Jin|first7=Jian|date=2015-03-18|title=The first structure-activity relationship studies for designer receptors exclusively activated by designer drugs|journal=ACS Chemical Neuroscience|volume=6|issue=3|pages=476–484|doi=10.1021/cn500325v|issn=1948-7193|pmc=4368042|pmid=25587888}} 13. ^{{Cite journal|last=Marchant|first=Nathan J.|last2=Whitaker|first2=Leslie R.|last3=Bossert|first3=Jennifer M.|last4=Harvey|first4=Brandon K.|last5=Hope|first5=Bruce T.|last6=Kaganovsky|first6=Konstantin|last7=Adhikary|first7=Sweta|last8=Prisinzano|first8=Thomas E.|last9=Vardy|first9=Eyal|date=January 2016|title=Behavioral and Physiological Effects of a Novel Kappa-Opioid Receptor-Based DREADD in Rats|journal=Neuropsychopharmacology|volume=41|issue=2|pages=402–409|doi=10.1038/npp.2015.149|issn=1740-634X|pmc=5130116|pmid=26019014}} 14. ^{{Cite web|url=https://www.hellobio.com/stability-of-water-soluble-dreadd-ligands-in-solution-a-technical-review/|title=Stability of Water-Soluble DREADD Ligands in Solution - A Technical Review|last=|first=|date=|website=HelloBio.com|language=en|archive-url=|archive-date=|dead-url=|access-date=2018-12-05}} 15. ^{{Cite web|url=https://www.hellobio.com/clozapine-n-oxide-stability-solubility-review/|title=Clozapine N-oxide (CNO) freebase stability and storage|last=|first=|date=|website=HelloBio.com|language=en|archive-url=|archive-date=|dead-url=|access-date=2018-12-05}} 16. ^{{cite journal | vauthors = Urban DJ, Roth BL | title = DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility | journal = Annual Review of Pharmacology and Toxicology | volume = 55 | issue = 1 | pages = 399–417 | date = 2015-01-06 | pmid = 25292433 | doi = 10.1146/annurev-pharmtox-010814-124803 }} 17. ^1 {{cite journal | vauthors = Zhu H, Roth BL | title = Silencing synapses with DREADDs | journal = Neuron | volume = 82 | issue = 4 | pages = 723–5 | date = May 2014 | pmid = 24853931 | pmc = 4109642 | doi = 10.1016/j.neuron.2014.05.002 }} 18. ^{{cite journal | vauthors = Smith RS, Hu R, DeSouza A, Eberly CL, Krahe K, Chan W, Araneda RC | title = Differential Muscarinic Modulation in the Olfactory Bulb | journal = The Journal of Neuroscience | volume = 35 | issue = 30 | pages = 10773–85 | date = July 2015 | pmid = 26224860 | pmc = 4518052 | doi = 10.1523/JNEUROSCI.0099-15.2015 }} 19. ^{{cite journal | vauthors = Ferguson SM, Eskenazi D, Ishikawa M, Wanat MJ, Phillips PE, Dong Y, Roth BL, Neumaier JF | title = Transient neuronal inhibition reveals opposing roles of indirect and direct pathways in sensitization | journal = Nature Neuroscience | volume = 14 | issue = 1 | pages = 22–4 | date = January 2011 | pmid = 21131952 | pmc = 3058296 | doi = 10.1038/nn.2703 }} 20. ^{{cite journal | vauthors = Coward P, Wada HG, Falk MS, Chan SD, Meng F, Akil H, Conklin BR | title = Controlling signaling with a specifically designed Gi-coupled receptor | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 95 | issue = 1 | pages = 352–7 | date = January 1998 | pmid = 9419379 | pmc = 18222 | doi = 10.1073/pnas.95.1.352 | jstor = 44466 | bibcode = 1998PNAS...95..352C }} 21. ^{{cite journal | vauthors = Mueller KL, Hoon MA, Erlenbach I, Chandrashekar J, Zuker CS, Ryba NJ | title = The receptors and coding logic for bitter taste | journal = Nature | volume = 434 | issue = 7030 | pages = 225–9 | date = March 2005 | pmid = 15759003 | doi = 10.1038/nature03352 | bibcode = 2005Natur.434..225M }} Further reading{{refbegin}}
1 : Signal transduction |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。